11:45 AM EDT, 07/28/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We adjust our target price to $115 from $121, 20.5x our 2026 EPS estimate after Q2 FY 25 earnings. We lower our 2025 EPS estimate to $4.94 from $4.99 and our 2026 EPS view to $5.60 from $5.64. We think RVTY's Q2 results came in slightly better than expected despite the company navigating a fluid operating environment, in which it continues to face a number of challenges. Q2 revenue of $720M, up a solid 4.1% Y/Y with 3% organic growth, was better than anticipated. The Life Sciences segment showed solid momentum, in our view, with revenue rising by a remarkable 5% Y/Y to $366M (with 4% organic growth) despite a tough business environment, while the Diagnostics segment revenue rose by a more modest 3% Y/Y to $354M. Although there are number of regulatory and business uncertainties in the near term, we think RVTY continues to be well positioned to support pharmaceutical and biotech customers in the long run given its focus on innovation and solid capabilities.